Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College was founded in 1957 by Professor Jiadong Deng, pioneer of hematology in China. The hospital moved to Sichuan in the 1970s and returned to Tianjin in 1982. The hospital is the largest national-level professional medical institution of scientific research-type hematopathy in China, which integrates medical treatment, scientific research, education and health services. As a tertiary-A specialist hospital, it has a total of 804 beds at present. The hospital has an anemia diagnosis and treatment center, leukemia diagnosis and treatment center, thrombostasis diagnosis and treatment center, stem cell transplantation center, lymphoma diagnosis and treatment center, MDS diagnosis and treatment center, pediatric hematology diagnosis and treatment center, comprehensive diagnosis and treatment center, regenerative medicine diagnosis and treatment center, hematology emergency center, critical medical diagnosis and treatment center, hematopathology diagnostic center and clinical testing center. With a complete set of specialties, the annual number of diagnoses and treatments exceeded 300,000. It is a top institution for the diagnosis and treatment of hematological diseases in China. From 2010 to 2022, the hospital ranked first in the China Hospital Specialty Reputation List (Hematology) for 13 consecutive years. With the specialty of hematology nursing as its specialty, the hospital initiated the "Demonstration Project of High-quality Nursing Service" of the Ministry of Health, and was awarded the advanced units of "Demonstration Project of High-quality Nursing Service" in Tianjin Health System and the first batch of "High-quality Nursing Service.
Lymphoma diagnosis and treatment centers mainly diagnose and treat "lymphatic system tumors such as malignant lymphoma, multiple myeloma, acute/chronic lymphocytic leukemia (collectively: lymphoma)". The center consists of the first ward, the second ward, the hematopoietic stem cell transplantation ward and the laboratory, with a total of 71 general beds and 10 isolation bin transplantation beds. The center has a high-level clinical diagnosis, treatment and research team consisting of 5 healthcare professionals with senior and 6 deputy senior titles as the backbone. The center has 7 postgraduate supervisors (2 doctoral supervisors). Clinical treatment at the center is characterized by precise diagnosis and overall treatment stratified by prognosis. The laboratory focuses on the molecular pathogenesis and effective treatment strategies of lymphoid tumors, focusing on the effect and mechanism of genetic abnormality of tumor cells and abnormality of immune microenvironment on the occurrence, development and drug resistance of lymphoma and myeloma.
- Director, Lymphoma Diagnosis and Treatment Center, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
- Director of Tianjin Cord Blood Hematopoietic Stem Cell Bank
- Special allowance experts from the State Council and young and middle-aged experts from the National Health Commission
- Member of the International Myeloma Society (IMS)
- Member of the Expert Committee of the International Myeloma Working Group (IMWG)
- Editorial Board of Blood Advances
- Honorary Chairman of the Professional Committee on Hematologic Oncology of the Chinese Anticancer Association
- Vice Chairman, Lymphoma Expert Committee, Chinese Society of Clinical Oncology
- Vice Chairman of Hematology Branch of Chinese Hospital Association
- Vice Chairman of Hematology Professional Committee of Chinese Medical Education Association
- Vice President of the Sixth Council of Tianjin Anti-Cancer Association
- Editorial Board of 6 Core Journals such as Chinese Journal of Hematology
- Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
- Assistant Director of Lymphoma Diagnosis and Treatment Center
- Deputy Group Leader, Lymphoma Group, Professional Committee of Hematologic Oncology, Chinese Anticancer Association
- Member of the International Myeloma Society (IMS)
- Member of the Expert Committee of the International Myeloma Working Group (IMWG)
- Standing Committee, Hematology Branch, Chinese Geriatrics Association
- Committee Member, Professional Committee of Lymphatic Hematology, Chinese Society of Geriatric Oncology
- Vice Chairman, Lymphoma Professional Committee, Tianjin Anti-Cancer Association
- Vice Chairman, Professional Committee of Critical Care Medicine in Oncology, Tianjin Anticancer Association
- Member of Chinese Multiple Myeloma Research Consortium
- Corresponding Editorial Board Member, Chinese Journal of Hematology
- Youth Director, China Anticancer Association
- Member, Secretary, China Multiple Myeloma Research Consortium
- Member of Tianjin Genetic Advisory Committee
- Chinese Young Oncology Scientist Award 2020
- Vice Chairman of the Second Youth Committee on Hematologic Oncology, Chinese Anticancer Association
- Member of the Youth Committee of the 11th Committee of the Hematology Branch of the Chinese Medical Association
- Member of the Translational Committee of Hematological Diseases, Chinese Anticancer Association
- Member of the Professional Committee of Oncology and Nephrology of the Chinese Anticancer Association
- Professional Committee of Elderly Oncology, Tianjin Anticancer Association
- The First Level Talents of Tianjin "131" Innovative Talents Training Project
- Young Medicine Brilliant of Tianjin Health and Family Planning Industry High-level Talents Selection and Training Project
